First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers

• Autores principales: Macarena Hernández-Jiménez (Autor), Samuel Martín-Vílchez (Autor), Dolores Ochoa (Autor), Gina Mejía-Abril (Autor), Manuel Román (Autor), Paola Camargo-Mamani (Autor), Sergio Luquero-Bueno (Autor), Bernd Jilma (Autor), María A. Moro (Autor), Gerónimo Fernández (Autor), David Piñeiro (Autor), Marc Ribó (Autor), Víctor M. González (Autor), Ignacio Lizasoain (Autor), Francisco Abad-Santos (Autor)
• Formato: Libro
• Publicado: Elsevier, 2022-06-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

ApTOLL is an aptamer that antagonizes Toll-like receptor 4 and improves functional outcomes in models of ischemic stroke and myocardial infarction. The aim of this study was to characterize the safety and pharmacokinetics of ApTOLL in healthy volunteers. A first-in-human dose-ascending, randomized,...